Evidence map›Paper›PMID 29146677›Full record

ReviewAmerican journal of physiology. Gastrointestinal and liver physiology2018

Functional role and therapeutic targeting of microRNAs in inflammatory bowel disease.

Artin Soroosh, Marina Koutsioumpa, Charalabos Pothoulakis, Dimitrios Iliopoulos

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of physiology. Gastrointestinal and liver physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. MicroRNAs in Inflammatory Bowel Disease and Its Complications.International journal of molecular sciences · 2022
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Artin SorooshCenter for Systems Biomedicine, University of California at Los Angeles , Los Angeles, California.
Marina KoutsioumpaCenter for Systems Biomedicine, University of California at Los Angeles , Los Angeles, California.
Charalabos PothoulakisCenter for Inflammatory Bowel Diseases, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine, University of California at Los Angeles , Los Angeles, California.
Dimitrios IliopoulosCenter for Systems Biomedicine, University of California at Los Angeles , Los Angeles, California.
University of California, Los Angeles · US

Funding

Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
Mechanisms of Neurotensin in Intestinal InflammationR01DK060729 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI POTHOULAKIS, CHARALABOS · 2002 to 2017
$5.0M
SUBSTANCE P AND INTESTINAL INFLAMMATIONR01DK047343 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI POTHOULAKIS, CHARALABOS · 1994 to 2014
$4.2M
Characterization and Targeting of MiR-24 Network in ColitisR01DK110003 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI POTHOULAKIS, CHARALABOS · 2016 to 2020
$1.7M
NIDDK NIH HHS P30 DK041301NIDDK NIH HHS R01 DK047343NIDDK NIH HHS R01 DK060729NIDDK NIH HHS R01 DK110003
6 · The paper itself

Abstract

Inflammatory bowel diseases (IBD) are chronic inflammatory gastrointestinal diseases, primarily consisting of ulcerative colitis and Crohn's disease. The complex nature of the disease, as well as the limited therapeutic options characterized by low efficiency and major side effects, highlights the importance of developing novel strategies of therapeutic intervention in IBD. Susceptibility loci related to IBD are present only in a small percentage of IBD patients, implying that epigenetic modifications could influence the pathogenesis of the disease. MicroRNAs (miRNAs) are small noncoding RNAs that regulate multiple molecular pathways involved in IBD pathobiology. MiRNA inhibitors targeting the IBD-activated miRNAs could have therapeutic value for IBD patients. This review provides an overview of the recent advances in miRNA biology related to IBD pathogenesis and the pharmacological development of miRNA-based therapeutics.

Indexed as

AnimalsDisease Models, AnimalGene Expression RegulationGenetic LociGenetic MarkersGenetic Predisposition to DiseaseGenetic TherapyHumansInflammatory Bowel DiseasesMicroRNAsOligonucleotides, AntisensePhenotypeSignal TransductionTranscriptomeGenetic MarkersMicroRNAsOligonucleotides, Antisenseantisense therapeuticschemical modificationsinflammatory bowel diseasemicroRNA

Identifiers

PMID29146677
PMCPMC5866423
OpenAlexW2768589279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.